Bridion Injection, Solution
Product Images NDC 0006-5423

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Bridion (NDC 0006-5423). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Merck Sharp & Dohme Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Bridion 01)

Chemical structure of sugammadex, the active ingredient in BRIDION injection, solution. The structure shows a cyclic molecule with multiple sugar units and sulfur atoms, including sodium carboxylate groups, typical of the sugammadex molecule.*

FDA Label Image

Chemical Structure (Bridion 02)

Chemical structure diagram of sugammadex, the active ingredient in BRIDION 100 mg/mL injection solution. The illustration displays the molecular arrangement including rings, hydroxyl groups, sodium carboxylate groups, and sulfur atoms characteristic of sugammadex.*

FDA Label Image

Figure 1 (Bridion 03)

A cumulative recovery rate chart comparing the recovery times of sugammadex 2 mg/kg and neostigmine 0.05 mg/kg after rocuronium administration. The x-axis represents time to recovery in minutes (0 to 120), and the y-axis represents cumulative recovery rate (0.0 to 1.0). Sugammadex shows faster recovery with median times around 1.4 minutes versus 21.5 minutes for neostigmine, using medians and quartiles based on product-limit estimates.*

FDA Label Image

Figure 2 (Bridion 04)

A Kaplan-Meier cumulative recovery rate curve comparing the recovery times of two treatments: sugammadex 2 mg/kg and neostigmine 0.05 mg/kg when combined with vecuronium. The graph plots cumulative recovery rate against time to recovery in minutes, showing median recovery times of 2.1 minutes for sugammadex and 29.0 minutes for neostigmine. The chart includes censored observations and is based on product-limit estimates from sample sizes of 48 and 45, respectively.*

FDA Label Image

Principal Display Panel (2 mL Vial Carton)

Packaging label for BRIDION (sugammadex) Injection, 200 mg/2 mL (100 mg/mL), an intravenous injection solution. The label indicates 10 single-dose 2 mL vials per package. The labeler is Merck Sharp & Dohme LLC. The packaging is predominantly white with gray accents and includes barcodes and regulatory information.*

FDA Label Image

Principal Display Panel (5 mL Vial Carton)

Packaging label for Bridion (sugammadex) Injection 500 mg/5 mL (100 mg/mL) solution for intravenous use. The label indicates it is provided in 10 single-dose 5 mL vials. The labeler is Merck Sharp & Dohme LLC. The design includes dosage strength, usage instructions, a barcode, and storage information, with orange and black text on a white background.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.